What I am working with: WXT · peptide mapping.
The units are where I keep going wrong, so please be explicit about them.
I have sanity-checked the order of magnitude and it seems right, which is not the same as being right.
Is my approach right even if my number is wrong?
Stated carefully, sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.
If testing multiple vials, state how many you tested and why you chose those vials.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemIt helps to be literal here: if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.
Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
In practice, published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
In practice, two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
I would treat a "complies with" statement without sampling details as a claim rather than as evidence.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 18 Apr 2026 by Dr_Aoife_Brennan — added the method parameters
The failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
If testing multiple vials, state how many you tested and why you chose those vials.
Most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.